Everolimus de novo in liver transplantation

Gastroenterologie Clinique et Biologique

Volumn 33, Issue SUPPL. 4, 2009, Pages

  Calmus, Y ^a   Durrbach, A ^b  

^a Hôpital Cochin ^*  (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAPAMYCIN; RIFAMPICIN; STEROID; TACROLIMUS;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER RISK; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEPATIC ARTERY; HEPATIC ARTERY THROMBOSIS; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RATE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCELE; MORTALITY; MOUTH ULCER; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; RISK REDUCTION; SAMPLE SIZE; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; WOUND DEHISCENCE;

CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER TRANSPLANTATION; PLACEBOS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 71149106640     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(09)73161-6     Document Type: Article

References (22)

1. Augustine J.J., Bodziak K.A., and Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 67 (2007) 369-391
2. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98 (2008) 923-930
3. Watson C.J., Friend P.J., Jamieson N.V., Frick T.W., Alexander G., Gimso A.E., et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 67 (1999) 505-509
4. Pridohl O., Heinemann K., Hartwig T., Witzigmann H., Lamesch P., Fangmann J., et al. Low-dose immunosuppression with FK-506 and sirolimus after liver transplantation: 1-year results. Transplant Proc 33 (2001) 3229-3231
5. Weisner R.H., and For the Rapamune Liver Transplant Study Group. The safety and effi cacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthoptic liver transplant recipients. Results from a pilot study [Abstract]. Hepatology 36 (2002) 208A
6. Dunkelberg J.C., Trotter J.F., Wachs M., Bak T., Kugelmas M., Steinberg T., et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 9 (2003) 463-468
7. Kneteman N.M., Oberholzer J., Al Saghier M., Meeberg G.A., Blitz M., Ma M.M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 (2004) 1301-1311
8. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 24 (2002) 53-58
9. Eisen H.J., Tuzcu E.M., Dorent R., Kobashigawa J., Mancini D., Valantine- von Kaeppler H.A., et al. Everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. N Engl J Med 349 (2003) 847-858
10. Abecassis M., Basadonna G., Bunnapradist S., Chan L., Cibrik D., Cooper M., et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 85 (2008) 821-826
11. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., Haas T., et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78 (2004) 1332-1340
12. Vítko S., Margreiter R., Weimar W., Dantal J., Kuypers D., Winkler M., et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5 (2005) 2521-2530
13. Levy G., Schmidli H., Punch J., Tuttle-Newhall E., Mayer D., Neuhaus P., et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 12 (2006) 1640-1648
14. Vitko S., Wlodarczyk Z., Kyllönen L., Czajkowski Z., Margreiter R., Backman L., et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 6 (2006) 531-538
15. Ciancio G., Burke G.W., Gaynor J.J., Ruiz P., Roth D., Kupin W., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 81 (2006) 845-852
16. Flechner S.M., Goldfarb D., Solez K., Modlin C.S., Mastroianni B., Savas K., et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 83 (2007) 883-892
17. Pearson T.C., Mulgaonkar S., Patel A., Scandling J., Shidban H., Weir M., et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the spare-the-nephron (STN) trial (abstract). Am J Transplant 8 (2007) 213
18. Lebranchu Y., Etienne I., Touchard G., Thervet E., Westeel P.F., Toupance O., et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) (abstract). Am J Transplant 7 (2007) 160
19. McAlister V.C., Peltekain K.M., Malatjalian D.A., Colohan S., Macdonald S., Bitter-Suermann H., et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 7 (2001) 701-708
20. Trotter J.F., Wachs M., Bak T., Trouillot T., Stolpman N., Everson G.T., et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 7 (2001) 343-431
21. ® US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection. Lancet 356 (2000) 194-202
22. Toso C., Meeberg G.A., Bigam D.L., Oberholzer J., Shapiro A.M., Gutfreund K., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83 (2007) 1162-1168